Abstract:BACKGROUND:Orthotopic liver transplantation (OLT) improves the prognosis of patients with hepatocellular carcinoma (HCC). Moreover, the complement system is a powerful immune effector that can affect liver function and process of liver cirrhosis. However, studies correlating the complement system with tacrolimus metabolism after OLT are scarce. In this study, the role of single nucleotide polymorphisms (SNPs) associated with the sixth complement component (C6) in tacrolimus metabolism was investigated during the early stages of liver transplantation. METHODS:The study enrolled 135 adult patients treated with OLT for HCC between August 2011 and October 2013. Ten SNPs in C6 gene and rs776746 in cytochrome P450 3A5 (CYP3A5) gene were investigated. The tacrolimus levels were monitored daily during 4 weeks after transplantation. RESULTS:Both donor and recipient CYP3A5 rs776746 allele A were correlated with decreased concentration/dose (C/D) ratios. Recipient C6 rs9200 allele G and donor C6 rs10052999 homozygotes were correlated with lower C/D ratios. Recipient CYP3A5 rs776746 allele A (yielded median tacrolimus C/D ratios of 225.90 at week 1 and 123.61 at week 2), C6 rs9200 allele G (exhibited median tacrolimus C/D ratios of 211.31 at week 1, 110.23 at week 2, and 99.88 at week 3), and donor CYP3A5 rs776746 allele A (exhibited median C/D ratios of 210.82 at week 1, 111.06 at week 2, 77.49 at week 3, and 85.60 at week 4) and C6 rs10052999 homozygote (exhibited median C/D ratios of 167.59 at week 2, 157.99 at week 3, and 155.36 at week 4) were associated with rapid tacrolimus metabolism. With increasing number of these alleles, patients were found to have lower tacrolimus C/D ratios at various time points during the 4 weeks after transplantation. In multiple linear regression analysis, recipient C6 rs9200 group (AA vs. GG/GA) was found to be related to tacrolimus metabolism at weeks 1, 2, and 3 (P = 0.005, P = 0.045, and P = 0.033, respectively), whereas donor C6 rs10052999 group (CC/TT vs. TC) was demonstrated to be correlated with tacrolimus metabolism only at week 4 (P = 0.001). CONCLUSIONS:Recipient C6 gene rs9200 polymorphism and donor C6 gene rs10052999 polymorphism are new genetic loci that affect tacrolimus metabolism in patients with HCC after OLT.

TLR10 Genotypes Affect Long-Term Graft Function in Tacrolimus-Treated Solid Organ Transplant Recipients.

[Relationship of Tumor Necrosis Factor Gene Polymorphism and Acute Graft-Versus-host Disease after Unrelated Allogeneic Hematopoietic Stem Cell Transplantation].

Association Between Tnf And Tnf Receptor Ii Gene Polymorphisms And Acute Graft-Versus-Host Disease In Unrelated Donor Allogeneic Haematopoietic Stem Cell Transplantation Within Chinese Population.

Influence of TLR4 Rs1927907 Locus Polymorphisms on Tacrolimus Pharmacokinetics in the Early Stage after Liver Transplantation

Donor and recipient polymorphisms of MAPK signaling pathway genes influence post-transplant liver function in Chinese liver transplant patients taking tacrolimus

Impact of Interleukin-10 Gene Polymorphisms on Tacrolimus Dosing Requirements in Chinese Liver Transplant Patients During the Early Posttransplantation Period.

Population Pharmacokinetics of Tacrolimus and CYP3A5, MDR1 and IL-10 Polymorphisms in Adult Liver Transplant Patients

Polymorphisms of Tumor Necrosis Factor-Α, Interleukin-10, Cytochrome P450 3A5 and ABCB1 in Chinese Liver Transplant Patients Treated with Immunosuppressant Tacrolimus

Association of CYP3A5 and IL-10 Polymorphisms with the Individual Dosage Regimen of Tacrolimus in Lung Transplantation Recipients

Influence of IL-18 and IL-10 Polymorphisms on Tacrolimus Elimination in Chinese Lung Transplant Patients

Polymorphisms in Cytotoxic T Lymphocyte Associated Antigen-4 Influence the Rate of Acute Rejection after Renal Transplantation in 167 Chinese Recipients.

Novel Single Nucleotide Polymorphisms in Interleukin 6 Affect Tacrolimus Metabolism in Liver Transplant Patients.

Gene Variations of Sixth Complement Component Affecting Tacrolimus Metabolism in Patients with Liver Transplantation for Hepatocellular Carcinoma.

Genetic factors underlying tacrolimus intolerance after liver transplantation

Polymorphisms in CTLA4 Influence Incidence of Drug-Induced Liver Injury after Renal Transplantation in Chinese Recipients.

Association of Hemoglobin Levels, CYP3A5, and NR1I3 Gene Polymorphisms with Tacrolimus Pharmacokinetics in Liver Transplant Patients

Impact of TBX21, GATA3, and FOXP3 Gene Polymorphisms on Acute Cellular Rejection after Liver Transplantation

FOXP3 Rs3761548 Polymorphism is Associated with Tacrolimus-Induced Acute Nephrotoxicity in Renal Transplant Patients

Genome-Wide Association Study of Tacrolimus Pharmacokinetics Identifies Novel Single Nucleotide Polymorphisms in the Convalescence and Stabilization Periods of Post-transplant Liver Function

Genetic Risk Factors for Post-Transplantation Diabetes Mellitus in Chinese Han Renal Allograft Recipients Treated with Tacrolimus.

Donor Il-18 Rs5744247 Polymorphism As A New Biomarker Of Tacrolimus Elimination In Chinese Liver Transplant Patients During The Early Post-Transplantation Period: Results From Two Cohort Studies